Premium
Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines
Author(s) -
Kennedy K. C.,
Qurollo B. A.,
Rose B. J.,
Thamm D. H.
Publication year - 2011
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2010.00248.x
Subject(s) - cancer research , epidermal growth factor , vandetanib , epidermal growth factor receptor , tyrosine kinase , receptor tyrosine kinase , protein kinase b , biology , heparin binding egf like growth factor , vascular endothelial growth factor , pi3k/akt/mtor pathway , phosphorylation , tyrosine phosphorylation , growth factor , cancer , endocrinology , medicine , receptor , signal transduction , microbiology and biotechnology , vegf receptors
Canine mammary gland tumours (CMTs) are the most common malignancies in female dogs. The receptor tyrosine kinase EGFR (erbb1), a receptor for epidermal growth factor (EGF) and related factors, mediates multiple oncogenic functions in human epithelial neoplasms. While previous studies have demonstrated EGFR expression in canine tumours, its function has not been studied in canine cancer. The purpose of this study was to determine the in vitro effects of EGF and vandetanib (ZD6474), a small molecule inhibitor of VEGFR‐2, EGFR and RET tyrosine kinases, on proliferation, invasion, survival and chemosensitivity in CMT cells. In low serum, EGF enhanced proliferation and chemotaxis, attenuated apoptosis, and stimulated vascular endothelial growth factor (VEGF) production. Vandetanib dose‐dependently inhibited EGFR phosphorylation as well as PI3K/Akt activation, and inhibited all EGF‐induced phenotypic effects. In conclusion, EGF stimulates multiple features promoting the malignant phenotype in CMT. Thus, CMT may be an important translational model for the investigation of novel EGFR‐directed therapies.